9:15 - 5:45 EDT | 6:15 - 2:45 PDT - All times are shown in EDT

09:00 am Coffee & Networking

9:25 am Chairman’s Opening Remarks

Advancing Clinical Scale Manufacturing Techniques for the Development of off-the-Shelf γδ T Cell-based Therapies

9:30 am Near-Limitless Quantities of GMP-Grade Gamma/Delta T-cells for Allogeneic Application


• PhosphoGam developed a new platform for limitless supply of gamma/ delta T-cells.
• The innovative direct-expansion platform produces limitless quantities of gamma/delta T-cells through a GMP-closed system.
• Removing the constrain on the supply of allogeneic cells enables a revolution in cell therapy treatment strategies, including dosing, supply, efficacy, and cost

10:00 am Ex vivo Expansion and Genetic Engineering of Gamma Delta T cells


• Optimized a GMP compliant, ex vivo expansion protocol that is being developed for a clinical trial to treat childhood cancer
• Optimized methods to genetically engineer gamma delta T cells using transfection or viral vector transduction, including lentiviral and AAV vectors

10:30 am Allogenic Off the Shelf CAR T Cell Therapy


• Allogenic CAR Therapy
• Gamma Delta T Cell
• Ovarian and Mesothelioma tumor

11:00 am Morning Break & Group Networking

Genetically Engineering γδ T cells for Enhanced Potency & Efficacy

12:00 pm Single Cell Immune Repertoire and Molecular Analysis of In Vitro Expanded Cord Blood-Derived Gamma-Delta T Cells (CBGDT)

  • Alice Cheung Senior Research Scientist, Singapore General Hospital, Assistant Professor, Duke-NUS Medical School


• Complex activation profile governs the cytotoxic activity of in vitro expanded CB-GDT.
• Resemblance of expression signatures and repertoire compositions to known γδTILs, suggestive of efficacies for specific disease indications

12:30 pm A New Way of Engineering γδT Cells: An Alternative to CARs to Enhance Efficacy and Survival

  • Marta Barisa Senior Research Fellow, Developmental Biology & Cancer Section , Zayed Center for Research, Great Ormond St Hospital, University College London Great Ormond St Institute of Child Health


• Novel type of non-CAR, non-CCR γδT cell engineering to enhance efficacy against tumour targets
• Payload delivery to tumour microenvironment
• Efficacy in the absence of CAR-driven exhaustion and activationinduced cell death

1:00 pm Engineering Gamma Delta TCR for an Innovative Tumor Specific Cell Therapy


γδ TCR tend recognize antigens like Fab therefore they behave as
physiological CAR-Ts
• γδ TCR recognize transformed “stressed” cells sparing healthy tissue
• γδ TCR engineered T cells magnify the potential therapeutic activity of γδ T cell

1:30 pm Lunch & Networking

Genetically Engineering γδ T cells for Enhanced Potency & Efficacy

2:00 pm The Development of Multiple Gamma Delta T Cell Platforms For Use In Allogeneic CAR Therapies


• Characterization of gamma delta T cells as allogeneic pipeline products
• Unique gene engineering tailored to gamma delta T cells to enable next generation CAR technologies


2:30 pm γδ-Enriched CAR-T Cells for Bone-Targeted Adoptive Immunotherapy

  • Daniel Abate-Daga Daga Associate Member, Depts. of Immunology, GI Oncology & Cutaneous Oncology, Acting Assistant Director - Cell Therapies Facility , H. Lee Moffitt Cancer Center & Research Institute


• PSCA-targeted Vγ9Vδ2 CAR-T cells recognize and destroy prostate cancer cells.
• Vγ9Vδ2 CAR-T cells display maximum cytotoxic capacity when administered in combination with zoledronate.

3:00 pm Development of TGF-b Conditioned Gamma Delta T-Cells for Immunotherapy of Cancer


• TGFb enhances the yield and anti-tumour activity of ex vivo expanded circulating gamma delta T-cells
• Trafficking of these cells to bone marrow is enhanced, enabling more effective treatment of haematological malignancies
• Combined use of genetic enhancement approaches and regional delivery can be used to effectively target these cells against solid tumours

3:30 pm Afternoon Break & Networking

Optimizing γδ T cell Trafficking for Development of Solid Tumor Treatment

4:00 pm Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links Vδ2+ γδ T Cell Alterations with Lymph Node Invasion

  • Anne-Sophie Chretien Associate Professor in Immunology, Paoli Calmettes Institute CRCM, Aix-Marseille University


• Vδ2+ γδ T cell alterations are assessable in peripheral blood using minimally invasive liquid biopsies
• Vδ2+ γδ T cell phenotypic alterations are already established at the time of diagnosis at early-stage breast cancer
• Terminally differentiated Vδ2+ γδ T cells expressing canonical markers of replicative senescence and exhaustion are significantly associated with tumor-draining lymph node invasion

4:30 pm Influence of TME on CAR T Cell Activity in LBCL


• How can we make γδ T cellular therapies more efficient in terms of bringing the immune cells into the tumour
• Discussing the adverse effect of the tumour itself and how to overcome the immuno suppressive tumour microenvironment.

5:00 pm Chairman’s Closing Remarks

5:15 pm Close of Summit